admiral update: co-occurrence of dnmt3a, npm1 & flt3 mutations in patients treated with gilteritinib
Published 1 year ago • 286 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
2:46
update of the admiral trial: gilteritinib vs salvage chemotherapy prior to hsct in flt-3 mutated aml
-
3:21
admiral analysis: survival by mutation status in gilteritinib-treated flt3 r/r aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
3:01
admiral: gilteritinib for r/r flt3-mutated aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:39
quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
19:50
3mensio ct pre-case planning: redo-tavr with prior evolut pro
-
16:13
3mensio ct pre-case planning: valve-in-valve tavr in trifecta
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:56
stellar: genomic sequencing of ctdna reveals additional driver mutations in richter's transformation
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
0:51
a novel adc, azd5335, for the treatment of solid tumors
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
0:41
cm alvim installation sequence
-
2:12
gilteritinib prolongs os in flt3 r/r aml: phase 3 admiral results
-
4:35
admiral trial results: gilteritinib versus salvage chemotherapy in patients with flt3-mutated re...
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
4:50
timing of driver mutations and clonal dynamics in mpns: a new paradigm for blood cancer development